MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Bromocriptine

CAS No. : 25614-03-3

MCE 站：Bromocriptine

产品活性：Bromocriptine 是一种有效的多巴胺 D2/D3 受体激动剂，结合多巴胺 D2 受体，pK_i 为 8.05±0.2。

研究领域：GPCR/G Protein  |  Neuronal Signaling

作用靶点：Dopamine Receptor

In Vitro: Bromocriptine stimulates [³⁵S]-GTPγS binding at D2 dopamine receptor expressed in CHO cells with pEC₅₀ of 8.15±0.05. Bromocriptine also is a strong inhibitor of brain nitric oxide synthase. The ergot alkaloid Bromocriptine (BKT) is found to act as a strong inhibitor of purified neuronal nitric oxide synthase (NOS) (IC₅₀=10±2 μM) whereas it is poorly active towards inducible macrophage NOS (IC₅₀>100 μM) . Bromocriptine is found to inhibit the activity of at least one human cytochrome P450 enzyme. Bromocriptine is a potent inhibitor of CYP3A4 with a calculated IC₅₀ value for the interaction of 1.69 μM.

In Vivo: Bromocriptine (a dopamine agonist) treatment (2 mg/kg, i.p.) group shows significant anti-immobility action as compared to control. When Bromocriptine administered 30 min after the last dose of 7 days MPE treatment ａnd subjected to FST, this dopaminergic agonist produces significant ａnd dose dependent potentiation of anti-immobility action of MPE (200 mg/kg, p.o.) as compared to MPE treatment alone. Bromocriptine (a dopamine agonist) treatment (2 mg/kg, i.p.) group shows a significant reduction of immobility time as compared to control. Bromocriptine administration after 7 days pretreatment with MPE (100 ａnd 200 mg/kg, p.o.) shows significant ａnd dose dependent potentiation of anti-immobility action of MPE as compared to MPE treatment alone. Intraperitoneal administration of Bromocriptine induces a significant, dose dependent (0.1 mg ａnd 1 mg/Kg) decrease in pain scores in CCI-IoN group when compared to sham ａnd its effect lasted for 6 h. The highest dose induces the highest score decrease, (P<0.01). As a positive control SKF8129 (DR1 agonist) is used. Its intraperitoneal administration induces a non-significant increase in the SMA score when compared to sham (saline-injected). Intracisternal administration of Bromocriptine decreases significantly the SMA score when compared to sham (saline-injected). Bromocriptine effect lasted for 20 min. Intraperitoneal administration of Bromocriptine induces a significant dose dependent decrease in SMA score in CCI-IoN?+?6-OHDA lesioned group compared to that of sham. Its effect lasted for 6 h. SKF81297 administration increases the allodynic score. Intracisternal administration of Bromocriptine decreases significantly the SMA score compared to that of sham (saline-injected rats) ａnd its effect lasted for 30 min.

相关产品：Clozapine N-oxide  |  MPTP hydrochloride  |  Oxidopamine hydrobromide  |  Chlorpromazine hydrochloride  |  L-DOPA  |  Bromocriptine mesylate  |  SCH-23390 hydrochloride  |  Pimozide  |  Cabergoline  |  Haloperidol  |  SKF 38393 hydrochloride  |  Brexpiprazole  |  Risperidone  |  Thioridazine hydrochloride  |  Fluphenazine dihydrochloride  |  Olanzapine  |  WAY-100635 Maleate  |  Dopamine hydrochloride  |  Quetiapine  |  Sulpiride  |  ONC206  |  Flunarizine dihydrochloride  |  Lurasidone  |  Perphenazine  |  Sumanirole maleate  |  SKF-82958 hydrobromide  |  Domperidone

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  染料试剂  |  PROTAC  |  同位素标记物  |  寡核苷酸

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。